RxDoctor Payments Data

Eric Moser, MD

Neurology · High Point, NCNPI 1386664019

Payments from drug & device makers

$1,370in general payments, 2019–2025

Across 47 payments — averaging $29.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$434
  • Biogen$164
  • Harmony Biosciences LLC$135
  • AbbVie$131
  • Boston Scientific$114
  • SPR Therapeutics, Inc$107
  • plus $287 from 9 others

What the payments were for

  • Consulting fees$1007%
  • Food & beverage$1,24191%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,370 in reported general payments places this provider in the 50th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$699,039
Medicare patients
302
Services billed
38,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$99,242
Enbrel MiniEtanercept11$80,880
UbrelvyUbrogepant45$77,035
Aimovig AutoinjectorErenumab-Aooe81$73,733
Xtampza ErOxycodone Myristate100$68,158
HizentraImmun Glob G(Igg)/Pro/Iga 0-5014$62,356
BelbucaBuprenorphine Hcl49$43,812
NeuproRotigotine34$32,285
BriviactBrivaracetam19$29,695
QuliptaAtogepant20$23,735
Nurtec OdtRimegepant Sulfate22$21,463
SavellaMilnacipran Hcl46$18,809
Gabapentin926$15,169
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen436$11,905
Buprenorphine33$10,792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Savella, Namzaric$131$127,051124 claims
PfizerNurtec Odt$14$21,46322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 566 neurology providers in North Carolina.

Other neurology in High Point

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →